IBIO vs. UPC, SBFM, GRAY, ENVB, SHPH, TENX, HILS, ADXS, TRVN, and CMMB
Should you be buying iBio stock or one of its competitors? The main competitors of iBio include Universe Pharmaceuticals (UPC), Sunshine Biopharma (SBFM), Graybug Vision (GRAY), Enveric Biosciences (ENVB), Shuttle Pharmaceuticals (SHPH), Tenax Therapeutics (TENX), Hillstream BioPharma (HILS), Ayala Pharmaceuticals (ADXS), Trevena (TRVN), and Chemomab Therapeutics (CMMB). These companies are all part of the "pharmaceutical preparations" industry.
iBio (NYSE:IBIO) and Universe Pharmaceuticals (NYSE:UPC) are both small-cap medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their profitability, media sentiment, earnings, dividends, analyst recommendations, risk, community ranking, valuation and institutional ownership.
Universe Pharmaceuticals has higher revenue and earnings than iBio.
iBio has a beta of -3.51, meaning that its stock price is 451% less volatile than the S&P 500. Comparatively, Universe Pharmaceuticals has a beta of 1.77, meaning that its stock price is 77% more volatile than the S&P 500.
Universe Pharmaceuticals' return on equity of 0.00% beat iBio's return on equity.
iBio and Universe Pharmaceuticals both received 0 outperform votes by MarketBeat users.
In the previous week, iBio had 1 more articles in the media than Universe Pharmaceuticals. MarketBeat recorded 1 mentions for iBio and 0 mentions for Universe Pharmaceuticals. iBio's average media sentiment score of 0.13 beat Universe Pharmaceuticals' score of 0.00 indicating that iBio is being referred to more favorably in the media.
7.9% of iBio shares are held by institutional investors. Comparatively, 0.2% of Universe Pharmaceuticals shares are held by institutional investors. 1.1% of iBio shares are held by insiders. Comparatively, 57.4% of Universe Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.
Summary
Universe Pharmaceuticals beats iBio on 6 of the 10 factors compared between the two stocks.
Get iBio News Delivered to You Automatically
Sign up to receive the latest news and ratings for IBIO and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding IBIO and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Related Companies and Tools
